2022 annual financial data
Halozyme Therapeutics 2022 Operating margin
Direct answer
Operating margin was 40.53%.
Operating income was 267,531,000 USD and net income was 202,129,000 USD.
Operating cash flow was 240,110,000 USD.
Get free Halozyme Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 660,116,000 USD
- Operating income
- 267,531,000 USD
- Net income
- 202,129,000 USD
- Operating cash flow
- 240,110,000 USD